Nordea Investment Management AB raised its stake in shares of Genomic Health, Inc. (NASDAQ:GHDX) by 8.2% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 58,025 shares of the medical research company’s stock after buying an additional 4,418 shares during the quarter. Nordea Investment Management AB owned about 0.17% of Genomic Health worth $1,889,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of GHDX. Russell Investments Group Ltd. grew its holdings in shares of Genomic Health by 25.4% during the first quarter. Russell Investments Group Ltd. now owns 24,322 shares of the medical research company’s stock worth $766,000 after purchasing an additional 4,925 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Genomic Health by 0.6% during the first quarter. Bank of New York Mellon Corp now owns 88,577 shares of the medical research company’s stock worth $2,789,000 after purchasing an additional 500 shares in the last quarter. Envestnet Asset Management Inc. grew its holdings in shares of Genomic Health by 13.6% during the first quarter. Envestnet Asset Management Inc. now owns 8,282 shares of the medical research company’s stock worth $259,000 after purchasing an additional 993 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. purchased a new position in shares of Genomic Health during the first quarter worth about $218,000. Finally, American International Group Inc. grew its holdings in shares of Genomic Health by 7.1% during the first quarter. American International Group Inc. now owns 11,505 shares of the medical research company’s stock worth $362,000 after purchasing an additional 765 shares in the last quarter. 88.90% of the stock is owned by institutional investors and hedge funds.

Several brokerages have recently commented on GHDX. Zacks Investment Research lowered Genomic Health from a “hold” rating to a “sell” rating in a report on Wednesday. Canaccord Genuity reaffirmed a “buy” rating and issued a $35.00 target price on shares of Genomic Health in a research note on Wednesday, September 27th. Jefferies Group LLC reaffirmed a “hold” rating and issued a $33.00 target price on shares of Genomic Health in a research note on Monday, June 12th. BidaskClub lowered Genomic Health from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. Finally, Piper Jaffray Companies reaffirmed a “hold” rating and issued a $31.00 target price on shares of Genomic Health in a research note on Thursday, August 3rd. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $31.83.

Genomic Health, Inc. (NASDAQ GHDX) opened at 31.93 on Thursday. The firm has a 50-day moving average price of $31.15 and a 200-day moving average price of $31.61. Genomic Health, Inc. has a 12-month low of $26.37 and a 12-month high of $33.97. The company’s market cap is $1.11 billion.

Genomic Health (NASDAQ:GHDX) last issued its earnings results on Tuesday, August 1st. The medical research company reported ($0.08) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.02). The firm had revenue of $85.50 million for the quarter, compared to the consensus estimate of $86.08 million. Genomic Health had a negative net margin of 1.50% and a negative return on equity of 4.33%. The company’s revenue for the quarter was up 4.3% on a year-over-year basis. During the same period last year, the firm earned ($0.18) earnings per share. On average, equities research analysts forecast that Genomic Health, Inc. will post ($0.02) earnings per share for the current fiscal year.

In other news, COO G Bradley Cole sold 5,000 shares of the business’s stock in a transaction on Tuesday, July 11th. The stock was sold at an average price of $32.53, for a total value of $162,650.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider James J. Vaughn sold 8,000 shares of the business’s stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $30.59, for a total value of $244,720.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 36,174 shares of company stock valued at $1,132,171. 46.20% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: This story was first reported by Marea Informative and is the property of of Marea Informative. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at http://www.mareainformativa.com/genomic-health-inc-ghdx-holdings-lifted-by-nordea-investment-management-ab/117036/.

Genomic Health Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Want to see what other hedge funds are holding GHDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genomic Health, Inc. (NASDAQ:GHDX).

Institutional Ownership by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Stock Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related stocks with our FREE daily email newsletter.